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MUSCLE ACTION POTENTIAL SCANS AND ULTRASOUND 
IMAGING IN NEUROFIBROMATOSIS Type 2 
ABSTRACT 
Introduction: The neuropathy in patients with neurofibromatosis type 2 (NF2) is difficult to 
quantify and to follow-up. This study compared three methods which may help to assess 
motor axon pathology in NF2 patients.  
Methods:  Nerve conduction studies in median nerves were supplemented by deriving motor 
unit number estimates (MUNE) from compound muscle action potential (CMAP) scans, and 
by high resolution ultrasound (US) peripheral nerve imaging. 
Results: CMAP amplitudes and nerve conduction velocity were normal in the vast majority of 
affected individuals, but CMAP scan MUNE revealed denervation and reinnervation in many 
of the peripheral nerves in NF2 patients. In addition, US nerve imaging enabled to monitor the 
size and number of schwannoma-like fascicular enlargements in the median nerve trunks.  
Conclusion: In contrast to conventional nerve conductions studies, CMAP scan MUNE in 
combination with US nerve imaging can quantify the NF2-associated neuropathy and may 
help to monitor disease progression and drug treatments.   
 
Key words: neurofibromatosis type 2, MUNE, denervation, reinnervation, ultrasound nerve 
imaging, neuropathy 
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INTRODUCTION 
Neurofibromatosis type 2 (NF2) is a hereditary tumor syndrome caused by loss of function 
mutations or deletion of the neurofibromatosis type 2 gene (NF2) located on chromosome 
22q12.1 This gene encodes merlin, a multi-functional cellular protein (see 2 for a recent 
review). Symptoms of neuropathy are common in NF2 as there are paresthesias, sensory loss, 
weakness, and muscle atrophy. Neuropathic pain, however, occurs in few patients only.3-7 The 
aim of the present study was to test novel methods which may help to quantify and follow up 
the NF2-associated neuropathy. For example, in the last few years, attempts to treat NF2 with 
pharmacological tools have led to the discovery that the anti-vascular antibody bevacizumab 
can at least stop the growth of tumors in many NF2 patients (e.g. 8-10). In addition, it has been 
described, recently, that an anti-angiogenesis treatment can improve the neuropathy in a 
murine sciatic nerve model of NF2. 11 However, the effect of pharmacological treatment 
strategies on the NF2-associated neuropathy in patients has not yet been described. One 
reason for this may be the lack of methods suitable to quantify motor axon pathology in NF2. 
A conventional electrophysiological examination of peripheral nerves includes, among 
other parameters, the determination of the amplitude of CMAPs. This parameter, however, 
offers only a rough estimation of the number of functionally intact motor axons in peripheral 
nerves. Reinnervation by collateral sprouting may keep the amplitude constant in spite of a 
loss in the number of motor units and axons. 12, 13 In fact, apparently normal CMAPs have 
been recorded in amyotrophic lateral sclerosis (ALS) although the number of intact motor 
axons was reduced by 50 %. 14 
In the last years, several methods have been developed to estimate the number of intact 
motor units in a peripheral nerve (MUNE). 15-17 It is now an accepted view that concurrent 
tracking of declines in MUNE and changes in single motor unit size over time have proven 
useful for research into the natural history of denervating disease, as well as the compensatory 
effects of collateral reinnervation. 17 
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Muscle action potential scans (CMAP scans), too, have been found to be useful in 
several types of motor neuron diseases and neuropathies. 18, 19  In the present study, we have 
used the MScanFit program, recently developed by one of the authors (HB) to model a CMAP 
scan. 20 Here we demonstrate that this analysis software can reveal denervation, but also 
reinnervation in peripheral nerves and muscles in NF2 patients.  
Peripheral nerve imaging carried out by high resolution ultrasound techniques can be 
performed with high spatial resolution 21 and findings on the median nerve have already been 
described. e.g. 22-24 It has been shown that his method allows the detection and quantification of 
schwannomas in peripheral nerves. 25 In the present study, we have combined CMAP scan 
MUNE with ultrasound imaging (US) to test whether these methods may help to quantify and 
to follow-up the NF2-associated neuropathy.   
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MATERIALS and METHODS 
 
Patients  
The study is based on measurements of 19 NF2 patients  aged between 12 to 70 years (mean + 
SE: 34.5 + 2.9 years; 12 males, 7 females). The diagnosis of NF2 in these patients was 
established on the basis of the modified NIH criteria for definite NF2 26 and verified by 
genetic testing. Other concurring causes for a neuropathy such as diabetes mellitus, 
alcoholism etc. were excluded by means of medical history and laboratory testing. All 
procedures were approved by the local ethics committee of Hamburg University Hospital and 
all patients gave written formal consent. Not all patients were examined by both, 
electrophysiology and nerve ultrasound imaging on both arms. This is due to organizational 
reasons (studies in two clinical departments), a change in the study design from one arm to 
both arms, and insufficient CMAP recordings (see Results for details). 
Electrophysiology 
The CMAP scans were performed in the neurofibromatosis outpatient clinic of the Hamburg-
Eppendorf University Hospital. QTRACW software (© Institute of Neurology, London) was 
available on a laptop with a Windows7 operating system. The other components of the set-up 
were the DS5 isolated bipolar constant current stimulator (Digitimer Ltd; Welwyn Garden 
City, UK), National Instruments USB-6251-BNC data acquisition device  (National 
Instruments Munich; Germany), the Hum Bug 50 Hz noise eliminator (Science Products; 
Hofheim, Germany), and a Grass LP511 AC amplifier; bandwith: 3 – 3 kHz. Self adhesive 
electrodes (Kendall ECG electrodes, H92SG) with a round conducting area of 15 mm in 
diameter were used for both stimulation and recording. The position of these electrodes were 
as in conventional use, stimulating the median nerve at the wrist, and recording CMAPs from 
the motor point of abductor pollicis brevis. For grounding, Neuroline 71410-M/1 electrodes 
(Ambu; Bad Nauheim, Germany) were used. 
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In addition, conventional electrodiagnostic testing of the median nerve (in particular 
determination of nerve conduction velocities in the upper and the forearm) was performed in 
the neurophysiology laboratory of the Hamburg-Eppendorf University Hospital by using a 
Nihon Kohden Neuropack X1. In median motor nerve studies, the recording site was the 
abductor pollicis brevis muscle. Stimulation sites were chosen at the wrist, the antecubital 
fossa, and the axilla.  
Muscle action potential scans  
Previously, the principles of CMAP scans or electrophysiological muscle scans have been 
described. 18, 19 These authors tested the importance of variables, such as stimulation 
frequency, stimulus duration, and the number of stimulus steps. 27. The analysis of CMAP 
scans is, however, not yet standardized.  The method used in the present study (MScanFit) has 
been described in detail. 20 MScanFit is available as part of the threshold tracking software 
QTRACW (© Institute of Neurology, University College London, distributed by Digitimer 
Ltd at www.digitimer.com). It was chosen for its convenience and speed. In brief, the peak 
CMAP amplitude was recorded while stimuli were delivered at a frequency of 2 Hz. The 
stimulus current was decreased from just supramaximal in 0.2% steps to a current strength 
just below the one necessary for the smallest measurable surface muscle action potential. The 
data plots were fitted by a model, in which the CMAP was made up of a number of SMUPs, 
each described by an amplitude, threshold and relative spread (or coefficient of variation) of 
threshold.  From this fitted model, the following derived parameters were used for the 
analyses: (1) number of SMUPs, (2) mean SMUP amplitude, and (3) largest SMUP 
amplitude.  
Ultrasound peripheral nerve imaging 
Ultrasound examinations were performed using a GE Healthcare LOGIQ E9 with a L8 18i 
linear hockey stick probe. To improve image quality, CrossXBeam and compound imaging 
software was used. Median nerves were scanned in the transverse plane along their entire 
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accessible length from axilla to wrist. Cervical roots and the plexus cervicobrachialis were not 
scanned and, therefore, not included in the analysis. The cross-sectional area (CSA) of the 
median nerve was recorded at predetermined sites: at the carpal tunnel, at 1/3 of the forearm, 
at the elbow, at ½ of the upper arm. Fascicle diameters were measured in each median nerve 
at three different sites, to generate normal diameter values (0.6 ± 0.13 mm; mean + SD).  
All “nerve lesions” within the scanned segments of the median nerve were included in the 
further analysis.  Nerve lesions were defined as focal well defined masses inside the 
epineurium with a middle to low homogeneous echogeneity, which allowed a clear 
differentiation of the lesion from unaffected fascicles. Only masses inside the epineurium with 
an enlargement of the fascicle diameter > 2fold in comparison to the mean fascicle diameter 
were defined as focal “nerve lesions” or schwannoma-like fascicular enlargements. Since 
small nerve lesions did not results in an increase of the CSA of the affected nerve segment, 
the CSA was not used to define nerve lesions.  
Statistics 
GraphPad Prism and statistical analysis software in QTRACP were used for basic statistics 
and scatter plots regression lines.  
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RESULTS 
 
MScanFits reveal number of functionally intact motor axons 
CMAP scans were recorded from 27 median nerves of 19 patients with NF2. The analysis is 
restricted to recordings with a stable amplitude of the maximal CMAP amplitude during the 
recording period with the maximal stimulus strength., a biphasic shape of the CMAP, no 
measurable responses to stimuli with low stimulation strength, the absence of disturbing 50 
Hz noise, and no voluntary movements. Representative examples of such recordings are 
illustrated in Fig. 1. Illustrated in the left column of Fig. 1 are CMAPs taken at different 
stimulation strengths. These representative examples illustrate the shape of the CMAPs. A 
superposition of all traces (up to several hundred) would reduce the clarity. The MScanFit 
analyses shown in the center and right column estimated not only the number of functionally 
intact motor units, but also the relative amplitudes of the component SMUPs.  Note that the 
maximal amplitudes of the CMAPs in the three examples of Fig. 1 are within a normal range 
of 5 - 8 mV (from base to peak amplitude). In contrast, the numbers of functionally intact 
motor axons differ clearly (from 35 to 120). It can also be seen that there is an inverse 
relationship between the number and the mean amplitude of the SMUPs. 
We also tested for a correlation between the estimated number of functionally intact 
motor fibers and other parameters (see Fig. 2). The graph in Fig. 2A shows, not surprisingly, 
that larger CMAP amplitudes tended to be made up of higher numbers of SMUPs. On the 
other hand, it can be seen that some CMAPs of normal amplitudes are seen in CMAP scans 
with a rather low number of functionally intact motor units. 
No clear relationship was found between the number of motor units and the 
conduction velocity of the median nerve in the upper or lower arm (Fig 2B). The conduction 
velocity in all patients was within a normal range. On the other hand, a strong negative 
correlation was found between the number of functionally intact motor units and the voltage 
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amplitude of SMUPs (Fig. 2C): peripheral nerves with a reduced number of motor axons 
show larger amplitudes of both the mean and the largest amplitude of SMUPs. This finding 
can be explained by reinnervation (see Discussion). 
The MScan MUNE data from the NF2 patients were compared with recordings 
obtained from 18 control subjects (age 20-67 years; mean + SE : 38.6 + 3.5; 12 females, 6 
males; 26 median nerves). A summary of the findings is illustrated in Fig. 3. In several of the 
NF2 patients, the number of functionally intact motor units is below 70 in spite of a CMAP 
amplitude above 5 mV. It can be seen that an increase in the mean amplitude of SMUPs is the 
underlying factor.  
 
Ultrasound peripheral nerve imaging in neurofibromatosis type 2. 
The cross sectional areas along the right and left median nerves of 14 NF2 patients were 
measured at the carpal tunnel, at 1/3 of the forearm, at the elbow, and at ½ of the upper arm.  
A summary of the findings is given in Table 1. These data from NF2 patients can be 
compared with reference values for ultrasonograpy data of median nerves in control subjects. 
22, 23 According to these data, we did not find a general enlargement of the CSA in the median 
nerves of NF2 patients. 
 On the other hand, a rather common observation in ultrasonographic images of NF2 
patients was the presence of schwannoma-like fascicular enlargements. These are focal well-
defined masses inside the perineurium with a middle to low homogeneous echogeneity, which 
allowed a clear differentiation from unaffected fascicles (see Fig. 3). All schwannoma-like 
fascicular enlargements (“nerve lesions”) were in direct relationship to the median nerve. A 
centric location inside the median nerve was observed in 95% whereas 5% had an eccentric 
location.  The contour exhibited well defined margins in 72%, poorly defined margins were 
found in 28%. The shape was fusiform in 87%, an oval shape was found in 13%. The internal 
echogeneity was homogeneous hypoechoic in 92%, a hyperechoic echogeneity was found in 
Page 9 of 30
John Wiley & Sons, Inc.
Muscle & Nerve
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
 10
8%.  An echogenic capsule, cystic changes, target signs or microlobulations were not found in 
any of the “lesions”. They were distant from each other and separated by nerve segments with 
normal fascicular structure. We did not detect any “nerve lesions” with diffuse and 
multilobular enlargement, which is characteristic for plexiform neurofibromas.  
  Schwannoma-like fascicular enlargements (“nerve lesions”) were seen in 15 median 
nerves of the 26 median nerves studied in 14 patients. The number of these fascicular 
enlargements varied between one and more than five in affected nerves. Table 2 summarizes 
the number and size of the “nerve lesions”. The diameter varied from >1.6 mm to 7 mm. For 
comparison, Schreiber et al.22 reported, for controls, a fascicular diameter in the forearm 
median nerve of  0.60 + 0.21 mm (mean + SD).   
 
Do schwannoma-like fascicular enlargements correlate with CMAP scan MUNE? 
In 14 NF2 patients, both CMAP scan MUNE and high resolution US images were obtained 
from 19 median nerves. We tested whether the number and size (diameter) of the 
schwannoma-like fascicular enlargements are correlated with the loss of functionally intact 
motor axons in the median nerves of these NF2 patients. The data are illustrated in Fig. 4. 
There was a correlation between the number of lesions and the loss of functionally intact 
motor units. However, the regression line did not reach significance (p = 0.065). This may be 
due to some patients in which denervation of the thenar muscle, but no “nerve lesions” were 
found. Furthermore, the diameter of the largest schwannoma-like fascicular enlargements 
clearly did not show a statistically significant correlation with the loss of functionally intact 
motor units. There might be more and larger “nerve lesions” in more proximal parts of the 
motor nerve fibers not covered by the US imaging in the present study.  
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DISCUSSION 
 
In the present study of NF2 patients, parameters of conventional neurography (maximal 
amplitude of the CMAP and nerve conduction velocity (CV)) were supplemented by CMAP 
scan MUNE and US imaging. The low amplitudes of the CMAP in some patients, together 
with normal CVs (Fig. 2), are in accordance with the description of an “axonal” type of 
neuropathy in NF2 patients. 3, 5, 6 In comparison to conventional techniques, however, the 
CMAP scan analyses can provide more quantitative data about the number of functionally 
intact motor axons in peripheral nerves and can help to quantify the extent of denervation. For 
example, a rather low number of motor units can be seen although the maximal amplitude of 
the CMAP is in the normal range (Fig. 2A).  
In addition, denervation is correlated with an increase in the voltage amplitude of 
SMUPs. In fact, the mean amplitude of SMUPs is larger in nerves with low as compared to 
high numbers of functionally intact motor fibers (Fig.2C). This observation is similar to 
earlier reports about the characteristics of SMUPs in NF2 3 and other partially denervated 
muscles such as in ALS, CMT, diabetic neuropathy and chronic demyelinating neuropathies. 
12,19, 28-31 According to these studies, it is very likely that reinnervation of denervated muscle 
endplates by means of axonal collateral sprouting 12 is the underlying mechanism in NF2 
patients, too. Taken together, the combination of a low number of functionally intact motor 
units and an increase in the mean amplitude of SMUPs (see Fig. 3) may help to support the 
diagnosis of neuropathy in NF2 patients. 
The high resolution ultrasonography nerve images revealed the presence of “nerve 
lesions” (i.e. schwannoma-like fascicular enlargements) in many NF2 patients (Fig. 4). These 
lesions might be small tumors (schwannomas) composed of proliferating Schwann cells as 
described in histological studies of sural nerve biopsies in NF2 patients. 3-6, 32 It has been 
described already that nerve schwannomas can be detected by ultrasound imaging and a case 
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report of a single NF2 patient has been published. 25, 33   Furthermore, multiple schwannomas 
along peripheral nerve trunks have been found in a recently developed murine model of NF2. 
34 It is, however, important to note that US imaging in the present study is restricted to the 
trunk of the median nerve between wrist and axilla.  On the other hand, the follow-up of such 
known “nerve lesions” may be sufficient, for example, to monitor the effect of drug 
treatments on the size of peripheral nerve tumors in NF2.   
The second parameter tested by US imaging in our study was the cross sectional areas 
of several regions in the median nerves outside schwannoma-like fascicular enlargements. 
The CSA data, however, did not differ from recently published reference values for 
ultrasonography of peripheral nerves (Table 1). 22, 23 It remains unclear, therefore, why nerve 
lesions/tumors in NF2 patients are restricted to few nerve regions only. 
 By demonstrating specific ultrasound changes in NF2 patients our study shows, that 
high resolution ultrasound can support the differential diagnosis of NF2-associated 
neuropathies from other hereditary or acquired neuropathies and also entrapment syndromes. 
In contrast to hereditary demyelinating neuropathies, e.g. CMT-1a and CMT-1b, we did not 
see a diffuse and extensive enlargement of the cross sectional area or fascicular diameter of 
the median nerve. 22, 24, 35 In NF2 patients, CSA values and fascicular diameter did not differ 
from standard values in unaffected nerve segments. Nerve segments at entrapments sites, e.g. 
the carpal tunnel, were similarly not affected in NF2 patients, allowing a differentiation from 
patients with hereditary neuropathy with liability to pressure palsies (HNPP) or entrapment 
syndromes. 24 
 Focal nerve enlargements are also described for acquired inflammatory 
demyelinating neuropathies, e.g. chronic inflammatory demyelinating polyradiculoneuropathy 
(CIDP). In CIDP patients either diffuse (37-41%) or multifocal enlargement of nerves is 
reported. 35, 36 Another ultrasound pattern seen in CIDP patients are large nerves with hypo- 
and hyperechoic fascicles. 37 As discussed above we did not find similar diffuse or multifocal 
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enlargements of the nerves / fascicles or changes in echogenicity in NF2 patients. In the NF2 
cohort, increased CSA values were only detectable in short and clearly defined segments 
associated with schwannoma-like fascicular enlargements.  
Only few reports describe ultrasound images of tumors associated with large 
sensomotoric peripheral nerves in NF1. 38-40 These appear with low homogeneous 
echogeneity in single or multiple fascicles. Recently, possible criteria to distinguish 
neurofibroma from schwannoma in high resolution US nerve images have been discussed. 41 
We would like to emphasize that all patients in our study were diagnosed as NF2 according to 
current diagnostic criteria.   
 The pathogenesis of neuropathy in NF2 patients is unclear. We, therefore, have 
analyzed our data to see whether they may support one of the hypotheses. One possible factor 
is the cumulative nerve compression caused by small tumors (schwannomas) or fascicular 
microlesions as discussed in earlier studies. 3-7, 32 Our data can give some support for this 
view. They indicate that the number of “nerve lesions” is higher in nerves with a loss of 
functionally intact motor axons (Fig. 5). The statistical analysis of this correlation, however, 
does not reach significance (Fig. 5). This may indicate that some tumors remain undetected by 
the nerve US imaging applied in the present study, which was restricted to the median nerve 
distally from the axilla. Also, we cannot exclude the possibility that other factors produce 
denervation in NF2 patients. Indeed, a clinical study describes that NF2 may affect peripheral 
nerve structures in a manner distinct from a compressive schwannoma. 42 
Referring to this, it has been described that the loss or diminution of merlin in 
peripheral nerve fibers may cause the neuropathy in NF2 patients independently from the 
presence of Schwann cell tumors. 43-45 The authors discuss an important role of merlin in 
neuronal cell types concerning neuromorphogenesis, axon structure maintenance and 
communication between axons and Schwann cells. It is possible, therefore, that NF2-related 
neuropathy is of multifactorial origin (Helen Morrison in 46). Also, there might be a 
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combination of several factors. For example, small lesions due to proliferating Schwann cells 
may be atypically destructive to axons with abnormal expression of merlin. Such a 
combination of factors could explain why there is an asymmetric dysfunction of motor axons 
in some NF2 patients and why the functionally intact axons retain the ability for collateral 
sprouting.  
 In summary, our data show that CMAP scan MUNE and high-resolution US 
peripheral nerve imaging are useful complimentary methods for assessing neuropathy in NF2 
patients. These non-invasive methods may be helpful not only for the diagnosis but also to 
follow-up the time course of muscle denervation and reinnervation. In addition, repeated 
nerve imaging would enable to observe the development in the number and size of 
schwannoma-like fascicular enlargements. From a practical point of view, these methods 
would be feasible for routine use in specialized centers.
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Abbreviations 
 
APB  M. abductor pollicis brevis 
ALS  amyotrophic lateral sclerosis  
CIDP   chronic inflammatory demyelinating polyradiculoneuropathy 
CMAP compound muscle action potential 
CMT  Charcot-Marie-Tooth neuropathy 
CSA  cross sectional area 
CV  conduction velocity 
HNPP  hereditary neuropathy with liability to pressure palsies 
MScan muscle action potential scan 
MUNE motor unit number estimate 
NF1  neurofibromatosis type 1 
NF2  neurofibromatosis type 2   
SMUP  single motor unit action potential 
US  ultrasound 
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TABLE 1.  
 
Cross sectional areas along the median nerves of NF2 patients. 
 
cross sectional area 
CSA 
NF2 
patients 
  
right median nerve number mean (mm
2
) + SD 
carpal tunnel 13 7.77 1.64 
1/3 of the forearm 14 7.79 2.72 
at the elbow 14 8.86 2.74 
½ of the upper arm 14 8.64 2.10 
left median nerve    
carpal tunnel 12 9.33 4.40 
1/3 of the forearm 12 7.33 1.30 
at the elbow 12 9.00 2.30 
½ of the upper arm 12 9.83 2.82 
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TABLE 2.  
 
Number and size of schwannoma-like fascicular enlargements 
in the median nerves of NF2 patients 
 
nerve 
lesions 
number 
 
NF2  
patients 
diameter 
1.6 – 2.5 
mm 
diameter 
2.6 – 5.0  
mm 
diameter 
> 5.0 
mm 
right 
 median nerve 
 
n = 14 
   
no lesion 5    
1 3 1 2  
2 3 3 3  
3 1 1 1 1 
4 1 1 2 1 
> 5 1 3 4 2 
left 
 median nerve 
 
n = 12 
   
no lesion 6    
1     
2 1 1 1  
3 3 3 6  
4 1 2 2  
> 5 1 6 2 3 
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,FIGURE LEGENDS 
 
FIGURE 1. Examples of CMAP scan analyses in three NF2 patients (A, B, C). The left 
column illustrates examples of CMAPs recorded from APB after stimulation of the median 
nerve at the wrist with subthreshold to supramaximal stimulation. The peak amplitudes 
(measured from base to the negative maximum) of all CMAPs are plotted for the various 
stimulation strengths (middle column). In the right column, the MScanFit program was used 
to derive a model with several SMUPs of different amplitudes to match the stimulus-response 
plots in the center column. The maximal number of functionally intact motor units and the 
mean voltage amplitude of the SMUPs for patients A, B, and C are given as insets in the 
middle and right column.   
 
FIGURE 2. Statistical analyses. The number of functionally intact motor units was tested for 
a possible correlation with other parameters. The insets in all graphs show the results of the fit 
with regression lines. Low numbers of SMUPs in APB do not show a correlation with the 
nerve CV in the forearm or upper arm (B). There is, however, a statistically significant 
correlation with the peak amplitude of the CMAP, the mean amplitude of SMUPs, and the 
voltage amplitude of the largest SMUP. 
 
FIGURE 3. Summary of MScan MUNE data in NF2 patients and from 26 median nerves of 
18 control subjects. The maximal amplitude of the CMAP, the number of functionally intact 
motor units, and the mean amplitude of SMUPs are illustrated in scatter (A, C) and dot plots 
(B, D). The bars in B, D indicate mean + SE. 
 
FIGURE 4. Examples of “nerve lesions” (i.e. schwannoma-like fascicular enlargements) in a 
NF2 patient. Longitudinal (a, b, c) and transverse (d, e, f) sonograms of the right median 
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nerve reveal well defined “lesions” of different diameters: (d) > 7 mm, (e) about 4 mm, (f) 
about 2 mm. The “lesions” show a middle to low homogeneous echogeneity and are located 
in direct continuity of the nerve inside the hyperechogenic epineurium. The outer borders of 
the nerve and the schwannoma-like fascicular enlargements are marked by yellow dotted 
lines.  
 
FIGURE 5. Correlation of findings in high resolution US nerve imaging with the number of 
functionally intact motor units detected by CMAP scan MUNE. The number (A) and the 
diameters of the largest schwannoma-like fascicular enlargements (B) in an affected nerve are 
illustrated. (A) Data from 20 median nerves of 14 NF2 patients. (B) Data from schwannoma-
like fascicular enlargements detected in 11 median nerves from 9 NF2 patients. The insets 
show egression line statistics.  
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FIGURE 1. Examples of CMAP scan analyses in three NF2 patients (A, B, C). The left column illustrates 
examples of CMAPs recorded from APB after stimulation of the median nerve at the wrist with subthreshold 
to supramaximal stimulation. The peak amplitudes (measured from base to the negative maximum) of all 
CMAPs are plotted for the various stimulation strengths (middle column). In the right column, the MScanFit 
program was used to derive a model with several SMUPs of different amplitudes to match the stimulus-
response plots in the center column. The maximal number of functionally intact motor units and the mean 
voltage amplitude of the SMUPs for patients A, B, and C are given as insets in the middle and right column.   
169x165mm (300 x 300 DPI)  
 
 
Page 26 of 30
John Wiley & Sons, Inc.
Muscle & Nerve
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
  
 
 
,FIGURE 2. Statistical analyses. The number of functionally intact motor units was tested for a possible 
correlation with other parameters. The insets in all graphs show the results of the fit with regression lines. 
Low numbers of SMUPs in APB do not show a reduction of the nerve conduction velocity in the forearm or 
upper arm (B). There is, however, a statistically significant correlation with the peak amplitude of the CMAP, 
the mean amplitude of SMUPs, and the voltage amplitude of the largest SMUP (A, C, D).  
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FIGURE 3. Summary of MScan MUNE data in NF2 patients and from 26 median nerves of 18 control 
subjects. The maximal amplitude of the CMAP, the number of functionally intact motor units, and the mean 
amplitude of SMUPs are illustrated in scatter (A, C) and dot plots (B, D). The bars in B, D indicate mean + 
SE.  
127x128mm (300 x 300 DPI)  
 
 
Page 28 of 30
John Wiley & Sons, Inc.
Muscle & Nerve
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
  
 
 
FIGURE 4. Examples of “nerve lesions” (i.e. schwannoma-like fascicular enlargements) in a NF2 patient. 
Longitudinal (a, b, c) and transverse (d, e, f) sonograms of the right median nerve reveal well defined 
“lesions” of different diameters: (d) > 7 mm, (e) about 4 mm, (f) about 2 mm. The “lesions” show a middle 
to low homogeneous echogeneity and are located in direct continuity of the nerve inside the hyperechogenic 
epineurium. The outer borders of the nerve and the schwannoma-like fascicular enlargements are marked 
by yellow dotted lines.  
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FIGURE 5. Correlation of findings in high resolution US nerve imaging with the number of functionally intact 
motor units detected by CMAP scan MUNE. The number (A) and the diameters of the largest schwannoma-
like fascicular enlargements (B) in an affected nerve are illustrated. (A) Data from 20 median nerves of 14 
NF2 patients including those patients without a “nerve lesion”. (B) Data from schwannoma-like fascicular 
enlargements detected in 11 median nerves from 9 NF2 patients. The insets show egression line statistics.  
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